Post-transplant diabetes mellitus in pediatric liver transplantation.
To determine the characteristics of pediatric liver transplant recipients who develop GI and/or PTDM, data on children undergoing their first liver transplant from the SPLIT database were analyzed (n = 1611). Recipient and donor characteristics that were evaluated included age at transplant, gender, race, primary disease, hospitalization status at transplant, BMI, recipient and donor CMV status, donor type, donor age, and primary immunosuppression. GI/PTDM was found in 214 individuals (13%) of whom 166 (78%) were diagnosed within 30 days of transplantation (early GI/PTDM). Multivariate analyses suggests that age >5 yr at transplant, hospitalization at transplant, a primary diagnosis other than BA, early steroid use, and tacrolimus use are associated with increased incidence of early GI. Routine monitoring for the development of GI and post-transplant diabetes is indicated in the short- and long-term care of children after liver transplantation.
Hathout
Eba
E
Division of Pediatric Endocrinology and Diabetes, Loma Linda University, Loma Linda, CA 92354, USA. ehathout@llu.edu
Alonso
Estella
E
Anand
Ravinder
R
Martz
Karen
K
Imseis
Essam
E
Johnston
Joyce
J
Lopez
James
J
Chinnock
Richard
R
McDiarmid
Sue
S
D000293:Adolescent; D015992:Body Mass Index; D002648:Child; D002675:Child, Preschool; D003587:Cytomegalovirus / Q000378:metabolism; D003920:Diabetes Mellitus / Q000209:etiology*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007223:Infant; D007231:Infant, Newborn; D007515:Islets of Langerhans / Q000166:cytology*; D016031:Liver Transplantation / Q000379:methods*; D008297:Male; D015999:Multivariate Analysis; D016559:Tacrolimus / Q000627:therapeutic use
D007166:Immunosuppressive Agents; D016559:Tacrolimus